[{"id":"a3950726-a4fc-4f10-89c7-7699eae995e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04954599","created_at":"2021-07-08T14:52:43.900Z","updated_at":"2024-07-02T16:35:08.431Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI","source_id_and_acronym":"NCT04954599","lead_sponsor":"Maastricht University Medical Center","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • CP-506"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-04-22"}]